(HealthDay)—A third surge of coronavirus cases now has a firm grip on the United States, with an average of 59,000 new infections being reported across…
COVID-19: Not all antibodies are equal in fighting the virus
When a person is infected by SARS-CoV-2, the number of antibodies able to neutralize the virus rapidly increases. Once the person recovers, their level decreases.…
Gut bacteria in multiple sclerosis: Probiotic or commensal, good or bad?
Researchers from the University of Vermont (UVM) have found that a bacterial species called Lactobacillus reuteri, commonly used in probiotics, can increase disease severity in…
Reopened schools in New York City not seeing COVID case spikes
(HealthDay)—Three weeks after becoming the first big urban area to reopen public schools since the pandemic began, New York City is not seeing a feared…
More than 40% of COVID-19 cases in US nursing homes are asymptomatic
More than 40% of coronavirus cases in US nursing homes are asymptomatic, new study finds Researchers looked at data from more than 500 nursing homes…
New modelling finds investing in childcare and aged care almost pays for itself
In the absence of an official analysis of the impact of the budget by gender the National Foundation for Australian Women has this morning published…
20% increase in flu vaccinations an ambitious but attainable goal, says researcher
A pharmacy researcher predicts more of us will roll up our sleeves for the influenza vaccine this fall thanks to the crash course we’ve all…
Peptides plus antibiotic combination may result in a more effective treatment for leishmaniasis
Leishmaniasis is caused by the protozoan Leishmania parasites which are transmitted by the bite of an infected sandfly. Although in rich countries this disease mainly…
Here's why the Home Edit ladies organize everything in rainbow order
There’s something just so aesthetically pleasing about neat and orderly items, whether it be a gorgeous bookshelf, a sorted pantry, or perfectly arranged closet. And…
Successful Phase 2 clinical trial for neflamapimod in mild-to-moderate Lewy body dementia
EIP Pharma announced on October 6 that a phase 2 study in patients with mild-to-moderate Lewy body dementia (LBD) demonstrated an improvement in cognition as…